Literature DB >> 20520641

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.

N von Bubnoff, C Rummelt, H Menzel, M Sigl, C Peschel, J Duyster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20520641     DOI： 10.1038/leu.2010.122

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

2.  Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.

Authors:  Jia Gu; Zhiqiong Wang; Min Xiao; Xia Mao; Li Zhu; Ying Wang; Wei Huang
Journal:  Cancer Biol Ther       Date:  2017-01-19       Impact factor: 4.742

3.  Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Authors:  Theodore C Tarver; Jason E Hill; Leena Rahmat; Alexander E Perl; Erkut Bahceci; Kenichi Mori; Catherine C Smith
Journal:  Blood Adv       Date:  2020-02-11

4.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Authors:  A B Williams; B Nguyen; L Li; P Brown; M Levis; D Leahy; D Small
Journal:  Leukemia       Date:  2012-07-13       Impact factor: 11.528

5.  Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.

Authors:  Chuanjiang Yu; Rama Krishna Kancha; Justus Duyster
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 6.  The Biology and Targeting of FLT3 in Pediatric Leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Front Oncol       Date:  2014-09-23       Impact factor: 6.244

Review 7.  FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.

Authors:  Francesca Biavasco; Robert Zeiser
Journal:  Int J Hematol       Date:  2022-04-23       Impact factor: 2.319

Review 8.  Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.

Authors:  Debora Capelli; Diego Menotti; Alessandro Fiorentini; Francesco Saraceni; Attilio Olivieri
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

9.  CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.

Authors:  Silvia Waldeck; Michael Rassner; Philip Keye; Marie Follo; Dieter Herchenbach; Cornelia Endres; Anne Charlet; Geoffroy Andrieux; Ulrich Salzer; Melanie Boerries; Justus Duyster; Nikolas von Bubnoff
Journal:  Mol Oncol       Date:  2020-02-13       Impact factor: 6.603

Review 10.  Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.

Authors:  Sebastian Scholl; Maximilian Fleischmann; Ulf Schnetzke; Florian H Heidel
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.